EXEL

Exelixis, Inc. 2001 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: Exelixis, Inc.
Reporting Period: Fiscal year ended December 31, 2001.
Business Model: A genomics-based drug discovery company focused on identifying novel targets for cancer, metabolic diseases, and agricultural products using model system genetics and comparative genomics. The company generates revenue primarily through strategic collaborations with pharmaceutical, biotechnology, and agrochemical firms, receiving upfront fees, research funding, milestone payments, and royalties.

Key Financial Metrics (Year Ended Dec 31, 2001)

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 65% to $41.0 million, driven by new collaborations with Protein Design Labs and Bristol-Myers Squibb (BMS), and accelerated revenue recognition from the termination of the Pharmacia collaboration.
• Expense Increases: R&D expenses rose 60% to $82.7 million due to increased personnel (69% increase in staffing costs), lab supplies, and licenses. General and administrative expenses increased 22% to $19.2 million.
• Acquisitions:
  • Genomica Corporation: Acquired in December 2001 for $110.0 million (stock-for-stock). This transaction significantly boosted cash reserves (acquired ~$109.6 million in cash/investments) but resulted in a $2.7 million goodwill impairment charge.
  • Artemis Pharmaceuticals: Acquired in May 2001 for $24.2 million, resulting in a $6.7 million charge for acquired in-process R&D.
• Collaboration Changes: The collaboration with Pharmacia was terminated by mutual consent (effective Feb 2002), eliminating future funding of ~$9.0 million annually but allowing Exelixis to reacquire rights to internal programs.

Guidance, Outlook, and Risks

• Profitability Outlook: The company expects to continue incurring net losses and negative operating cash flow for the foreseeable future. Significant additional capital will be required to fund R&D and clinical development.
• Liquidity: Management believes current cash, investments, and collaborator funding are sufficient to sustain operations for at least the next two years.
• Key Risks:
  • Dependence on Collaborations: Substantially all revenue is derived from collaborations. Failure to achieve milestones or renew agreements (e.g., BMS mechanism of action program expiring Sept 2002) could materially reduce revenue.
  • Regulatory and Clinical Risk: The company has no experience in clinical trials. Its most advanced asset, DEAE Rebeccamycin (in Phase II), faces significant regulatory uncertainty.
  • Intellectual Property: Risks regarding the ability to protect patents and potential infringement claims.
  • Accounting Changes: Adoption of SFAS 142 in 2002 will eliminate goodwill amortization, expected to reduce net loss by ~$4.7 million in 2002, though assets will be subject to annual impairment testing.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $227.7 million cash position against the projected increase in operating expenses for clinical trials.
• Collaboration Renewals: Monitor the status of the BMS mechanism of action agreement (expiring Sept 2002) and the potential impact of the Bayer acquisition of Aventis on the Agrinomics joint venture.
• DEAE Rebeccamycin Progress: Track the timeline and results of Phase II clinical trials for the in-licensed cancer compound.
• Goodwill Impairment: Assess the risk of future impairment charges on the $69.5 million in goodwill and intangibles, particularly regarding the Genomica and Artemis acquisitions.
• Revenue Recognition Policy: Confirm the impact of the accelerated revenue recognition from the Pharmacia termination on future revenue streams.